Sulfadoxine-pyrimethamine resistance in Plasmodium falciparum: A zoomed image at the molecular level within a geographic context

Acta Tropica

Volumn 125, Issue 2, 2013, Pages 163-190

  Abdul Ghani, Rashad ^a,b   Farag, Hoda F ^a   Allam, Amal F ^a  

^a ALEXANDRIA UNIVERSITY   (Egypt)

^b SANA A UNIVERSITY   (Yemen)

Author keywords

Dhfr; Dhps; Molecular markers; Plasmodium falciparum; Resistance; Sulfadoxine pyrimethamine

Indexed keywords

AMODIAQUINE; AMODIAQUINE PLUS ARTESUNATE; ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ DERIVATIVE; ARTESUNATE; CHLOROQUINE; DIHYDROARTEMISININ PLUS PIPERAQUINE; DIHYDROFOLATE REDUCTASE; DIHYDROFOLATE SYNTHETASE; MOLECULAR MARKER; PYRIMETHAMINE; PYRIMETHAMINE PLUS SULFADOXINE; SULFADOXINE; SYNTHETASE; UNCLASSIFIED DRUG;

DISEASE CONTROL; DISEASE TREATMENT; DRUG PRESCRIBING; DRUG RESISTANCE; EFFICIENCY MEASUREMENT; EPIDEMIOLOGY;

ANTIMALARIAL DRUG RESISTANCE; DRUG EFFICACY; DRUG STRUCTURE; DRUG TREATMENT FAILURE; GENE MUTATION; GEOGRAPHIC DISTRIBUTION; GOLD STANDARD; HUMAN; IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; NONHUMAN; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX MALARIA; REVIEW; SINGLE DRUG DOSE;

ANTIMALARIALS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DIHYDROPTEROATE SYNTHASE; DRUG COMBINATIONS; DRUG RESISTANCE; EVOLUTION, MOLECULAR; GENES, PROTOZOAN; GEOGRAPHY; HUMANS; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; POINT MUTATION; PYRIMETHAMINE; SULFADOXINE; TETRAHYDROFOLATE DEHYDROGENASE;

PLASMODIUM FALCIPARUM;

EID: 84871388444     PISSN: 0001706X     EISSN: 18736254     Source Type: Journal    
DOI: 10.1016/j.actatropica.2012.10.013     Document Type: Review

References (289)

1. A-Elbasit I.E., Khalil I.F., Elbashir M.I., Masuadi E.M., Bygbjerg I.C., Alifrangis M., Giha H.A. High frequency of Plasmodium falciparum CICNI/SGEAA and CVIET haplotypes without association with resistance to sulfadoxine/pyrimethamine and chloroquine combination in the Daraweesh area, in Sudan. European Journal of Clinical Microbiology & Infectious Diseases: Official Publication of the European Society of Clinical Microbiology 2008, 27:725-732.
2. Afsharpad M., Zakeri S., Pirahmadi S., Djadid N.D. Molecular monitoring of Plasmodium falciparum resistance to antimalarial drugs after adoption of sulfadoxine-pyrimethamine plus artesunate as the first-line treatment in Iran. Acta Tropica 2012, 121:13-18.
3. Ahmed A., Bararia D., Vinayak S., Yameen M., Biswas S., Dev V., Kumar A., Ansari M.A., Sharma Y.D. Plasmodium falciparum isolates in India exhibit a progressive increase in mutations associated with sulfadoxine-pyrimethamine resistance. Antimicrobial Agents and Chemotherapy 2004, 48:879-889.
4. Al-Farsi H.M., Al-Hashami Z.S., Bin Dajem S.M., Al-Sheikh A.A.H., Al-Qahtani A., Beja-Pereira A., Idris M.A., Babiker H.A. Source of drug resistant Plasmodium falciparum in a potential malaria elimination site in Saudi Arabia. Infection, Genetics and Evolution: Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases 2012, 12:1253-1259.
5. Al-Saai S., Kheir A., Abdel-Muhsin A.M., Al-Ghazali A., Nwakanma D., Swedberg G., Babiker H.A. Distinct haplotypes of dhfr and dhps among Plasmodium falciparum isolates in an area of high level of sulfadoxine-pyrimethamine (SP) resistance in eastern Sudan. Infection, Genetics and Evolution: Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases 2009, 9:778-783.
6. Al Harthi S.A. Detection of drug resistance markers for chloroquine and pyrimethamine-sulfadoxine in Jazan area, Saudi Arabia using PCR and restriction digestion. Journal of the Egyptian Society of Parasitology 2007, 37:17-30.
7. Alam M.T., de Souza D.K., Vinayak S., Griffing S.M., Poe A.C., Duah N.O., Ghansah A., Asamoa K., Slutsker L., Wilson M.D., Barnwell J.W., Udhayakumar V., Koram K.A. Selective sweeps and genetic lineages of Plasmodium falciparum drug-resistant alleles in Ghana. The Journal of Infectious Diseases 2011, 203:220-227.
8. Alifrangis M., Enosse S., Khalil I.F., Tarimo D.S., Lemnge M.M., Thompson R., Bygbjerg I.C., Ronn A.M. Prediction of Plasmodium falciparum resistance to sulfadoxine/pyrimethamine in vivo by mutations in the dihydrofolate reductase and dihydropteroate synthetase genes: a comparative study between sites of differing endemicity. The American Journal of Tropical Medicine and Hygiene 2003, 69:601-606.
9. Alifrangis M., Lemnge M.M., Ronn A.M., Segeja M.D., Magesa S.M., Khalil I.F., Bygbjerg I.C. Increasing prevalence of wildtypes in the dihydrofolate reductase gene of Plasmodium falciparum in an area with high levels of sulfadoxine/pyrimethamine resistance after introduction of treated bed nets. The American Journal of Tropical Medicine and Hygiene 2003, 69:238-243.
10. Alifrangis M., Lusingu J.P., Mmbando B., Dalgaard M.B., Vestergaard L.S., Ishengoma D., Khalil I.F., Theander T.G., Lemnge M.M., Bygbjerg I.C. Five-year surveillance of molecular markers of Plasmodium falciparum antimalarial drug resistance in Korogwe District, Tanzania: accumulation of the 581G mutation in the P. falciparum dihydropteroate synthase gene. The American Journal of Tropical Medicine and Hygiene 2009, 80:523-527.
11. Alker A.P., Mwapasa V., Purfield A., Rogerson S.J., Molyneux M.E., Kamwendo D.D., Tadesse E., Chaluluka E., Meshnick S.R. Mutations associated with sulfadoxine-pyrimethamine and chlorproguanil resistance in Plasmodium falciparum isolates from Blantyre, Malawi. Antimicrobial Agents and Chemotherapy 2005, 49:3919-3921.
12. Anderson T.J., Nair S., Jacobzone C., Zavai A., Balkan S. Molecular assessment of drug resistance in Plasmodium falciparum from Bahr El Gazal province, Sudan. Tropical Medicine & International Health: TM & IH 2003, 8:1068-1073.
13. Aponte J.J., Schellenberg D., Egan A., Breckenridge A., Carneiro I., Critchley J., Danquah I., Dodoo A., Kobbe R., Lell B., May J., Premji Z., Sanz S., Sevene E., Soulaymani-Becheikh R., Winstanley P., Adjei S., Anemana S., Chandramohan D., Issifou S., Mockenhaupt F., Owusu-Agyei S., Greenwood B., Grobusch M.P., Kremsner P.G., Macete E., Mshinda H., Newman R.D., Slutsker L., Tanner M., Alonso P., Menendez C. Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet 2009, 374:1533-1542.
14. Archibald H.M. Preliminary field trials on a new schizonticide. British Medical Journal 1951, 2:821-823.
15. Archibald H.M. The appearance of P. falciparum resistant to pyrimethamine in a northern Nigerian village. West African Medical Journal 1960, 9:21-25.
16. Asih P.B., Rogers W.O., Susanti A.I., Rahmat A., Rozi I.E., Kusumaningtyas M.A., Krisin Sekartuti, Dewi R.M., Coutrier F.N., Sutamihardja A., van der Ven A.J., Sauerwein R.W., Syafruddin D. Seasonal distribution of anti-malarial drug resistance alleles on the island of Sumba, Indonesia. Malaria Journal 2009, 8:222.
17. Aubouy A., Bakary M., Keundjian A., Mbomat B., Makita J.R., Migot-Nabias F., Cot M., Le Bras J., Deloron P. Combination of drug level measurement and parasite genotyping data for improved assessment of amodiaquine and sulfadoxine-pyrimethamine efficacies in treating Plasmodium falciparum malaria in Gabonese children. Antimicrobial Agents and Chemotherapy 2003, 47:231-237.
18. Aubouy A., Jafari S., Huart V., Migot-Nabias F., Mayombo J., Durand R., Bakary M., Le Bras J., Deloron P. DHFR and DHPS genotypes of Plasmodium falciparum isolates from Gabon correlate with in vitro activity of pyrimethamine and cycloguanil, but not with sulfadoxine-pyrimethamine treatment efficacy. The Journal of Antimicrobial Chemotherapy 2003, 52:43-49.
19. Bacon D.J., Mccollum A.M., Griffing S.M., Salas C., Soberon V., Santolalla M., Haley R., Tsukayama P., Lucas C., Escalante A.A., Udhayakumar V. Dynamics of malaria drug resistance patterns in the Amazon basin region following changes in Peruvian national treatment policy for uncomplicated malaria. Antimicrobial Agents and Chemotherapy 2009, 53:2042-2051.
20. Basco L., Ringwald P. [Drug-resistant malaria: problems with its definition and technical approaches]. Sante 2000, 10:47-50.
21. Basco L.K., de Pecoulas P.E., Wilson C.M., Le Bras J., Mazabraud A. Point mutations in the dihydrofolate reductase-thymidylate synthase gene and pyrimethamine and cycloguanil resistance in Plasmodium falciparum. Molecular and Biochemical Parasitology 1995, 69:135-138.
22. Basco L.K., Tahar R., Keundjian A., Ringwald P. Sequence variations in the genes encoding dihydropteroate synthase and dihydrofolate reductase and clinical response to sulfadoxine-pyrimethamine in patients with acute uncomplicated falciparum malaria. The Journal of Infectious Diseases 2000, 182:624-628.
23. Basco L.K., Tahar R., Ringwald P. Molecular basis of in vivo resistance to sulfadoxine-pyrimethamine in African adult patients infected with Plasmodium falciparum malaria parasites. Antimicrobial Agents and Chemotherapy 1998, 42:1811-1814.
24. Bassat Q., Alonso P.L. Drug resistance in malaria in developing countries. Antimicrobial Resistance in Developing Countries 2010, Springer, New York. A.D.J. Sosa, C.F. Amábile-Cuevas, D.K. Byarugaba, P.R. Hsueh, S. Kariuki, K.N. Okeke (Eds.).
25. Bell D.J., Nyirongo S.K., Mukaka M., Zijlstra E.E., Plowe C.V., Molyneux M.E., Ward S.A., Winstanley P.A. Sulfadoxine-pyrimethamine-based combinations for malaria: a randomised blinded trial to compare efficacy, safety and selection of resistance in Malawi. PLoS One 2008, 3:e1578.
26. Berens N., Schwoebel B., Jordan S., Vanisaveth V., Phetsouvanh R., Christophel E.M., Phompida S., Jelinek T. Plasmodium falciparum: correlation of in vivo resistance to chloroquine and antifolates with genetic polymorphisms in isolates from the south of Lao PDR. Tropical Medicine & International Health: TM & IH 2003, 8:775-782.
27. Bertin G., Briand V., Bonaventure D., Carrieu A., Massougbodji A., Cot M., Deloron P. Molecular markers of resistance to sulphadoxine-pyrimethamine during intermittent preventive treatment of pregnant women in Benin. Malaria Journal 2011, 10:196.
28. Bin Dajem S.M., Al-Farsi H.M., Al-Hashami Z.S., Al-Sheikh A.A., Al-Qahtani A., Babiker H.A. Distribution of drug resistance genotypes in Plasmodium falciparum in an area of limited parasite diversity in Saudi Arabia. The American Journal of Tropical Medicine and Hygiene 2012, 86:782-788.
29. Bin Dajem S.M., Al-Qahtani A. Analysis of gene mutations involved in chloroquine resistance in Plasmodium falciparum parasites isolated from patients in the southwest of Saudi Arabia. Annals of Saudi Medicine 2010, 30:187-192.
30. Biswas S. Associations of antifolate resistance in vitro and point mutations in dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum. Journal of Postgraduate Medicine 2004, 50:17-20.
31. Biswas S., Escalante A., Chaiyaroj S., Angkasekwinai P., Lal A.A. Prevalence of point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum isolates from India and Thailand: a molecular epidemiologic study. Tropical Medicine & International Health: TM & IH 2000, 5:737-743.
32. Bjorkman A., Phillips-Howard P.A. The epidemiology of drug-resistant malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene 1990, 84:177-180.
33. Bloland P. Drug Resistance in Malaria 2001, World Health Organization, Geneva.
34. Bonizzoni M., Afrane Y., Baliraine F.N., Amenya D.A., Githeko A.K., Yan G. Genetic structure of Plasmodium falciparum populations between lowland and highland sites and antimalarial drug resistance in Western Kenya. Infection, Genetics and Evolution: Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases 2009, 9:806-812.
35. Bonnet M., Roper C., Felix M., Coulibaly L., Kankolongo G.M., Guthmann J.P. Efficacy of antimalarial treatment in Guinea: in vivo study of two artemisinin combination therapies in Dabola and molecular markers of resistance to sulphadoxine-pyrimethamine in N'Zerekore. Malaria Journal 2007, 6:54.
36. Bouyou-Akotet M.K., Mawili-Mboumba D.P., Tchantchou T.D.D., Kombila M. High prevalence of sulfadoxine/pyrimethamine-resistant alleles of Plasmodium falciparum isolates in pregnant women at the time of introduction of intermittent preventive treatment with sulfadoxine/pyrimethamine in Gabon. The Journal of Antimicrobial Chemotherapy 2010, 65:438-441.
37. Brooks D.R., Wang P., Read M., Watkins W.M., Sims P.F., Hyde J.E. Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. European Journal of Biochemistry/FEBS 1994, 224:397-405.
38. Butcher G.A. Antimalarial drugs and the mosquito transmission of Plasmodium. International Journal for Parasitology 1997, 27:975-987.
39. Bwijo B., Kaneko A., Takechi M., Zungu I.L., Moriyama Y., Lum J.K., Tsukahara T., Mita T., Takahashi N., Bergqvist Y., Bjorkman A., Kobayakawa T. High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first-line treatment in Malawi. Acta Tropica 2003, 85:363-373.
40. Carter J.Y., Loolpapit M.P., Lema O.E., Tome J.L., Nagelkerke N.J., Watkins W.M. Reduction of the efficacy of antifolate antimalarial therapy by folic acid supplementation. The American Journal of Tropical Medicine and Hygiene 2005, 73:166-170.
41. Carter T.E., Warner M., Mulligan C.J., Existe A., Victor Y.S., Memnon G., Boncy J., Oscar R., Fukuda M.M., Okech B.A. Evaluation of dihydrofolate reductase and dihydropteroate synthetase genotypes that confer resistance to sulphadoxine-pyrimethamine in Plasmodium falciparum in Haiti. Malaria Journal 2012, 11:275.
42. Casey G.J., Ginny M., Uranoli M., Mueller I., Reeder J.C., Genton B., Cowman A.F. Molecular analysis of Plasmodium falciparum from drug treatment failure patients in Papua New Guinea. The American Journal of Tropical Medicine and Hygiene 2004, 70:251-255.
43. Certain L.K., Briceno M., Kiara S.M., Nzila A.M., Watkins W.M., Sibley C.H. Characteristics of Plasmodium falciparum dhfr haplotypes that confer pyrimethamine resistance, Kilifi, Kenya, 1987-2006. The Journal of Infectious Diseases 2008, 197:1743-1751.
44. Charles L.J., van der Kaay H.J., Vincke I.H., Brady J. The appearance of pyrimethamine resistance in Plasmodium falciparum following self-medication by a rural community in Ghana. Bulletin of the World Health Organization 1962, 26:103-108.
45. Charlesworth B. A hitch-hiking guide to the genome: a commentary on 'The hitch-hiking effect of a favourable gene' by John Maynard Smith and John Haigh. Genetical Research 2007, 89:389-390.
46. Chulay J.D., Watkins W.M., Sixsmith D.G. Synergistic antimalarial activity of pyrimethamine and sulfadoxine against Plasmodium falciparum in vitro. The American Journal of Tropical Medicine and Hygiene 1984, 33:325-330.
47. Clyde D.F., Shute G.T. Resistance of East African varieties of Plasmodium falciparum to pyrimethamine. Transactions of the Royal Society of Tropical Medicine and Hygiene 1954, 48:495-500.
48. Clyde D.F., Shute G.T. Resistance of Plasmodium falciparum in Tanganyika to pyrimethamine administered at weekly intervals. Transactions of the Royal Society of Tropical Medicine and Hygiene 1957, 51:505-513.
49. Cohuet S., Bonnet M., Van Herp M., Van Overmeir C., D'alessandro U., Guthmann J.P. Short report: molecular markers associated with Plasmodium falciparum resistance to sulfadoxine-pyrimethamine in the Democratic Republic of Congo. The American Journal of Tropical Medicine and Hygiene 2006, 75:152-154.
50. Contreras C.E., Cortese J.F., Caraballo A., Plowe C.V. Genetics of drug-resistant Plasmodium falciparum malaria in the Venezuelan state of Bolivar. The American Journal of Tropical Medicine and Hygiene 2002, 67:400-405.
51. Corredor V., Murillo C., Echeverry D.F., Benavides J., Pearce R.J., Roper C., Guerra A.P., Osorio L. Origin and dissemination across the Colombian Andes mountain range of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum. Antimicrobial Agents and Chemotherapy 2010, 54:3121-3125.
52. Cortese J.F., Caraballo A., Contreras C.E., Plowe C.V. Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America. The Journal of Infectious Diseases 2002, 186:999-1006.
53. Cortese J.F., Plowe C.V. Antifolate resistance due to new and known Plasmodium falciparum dihydrofolate reductase mutations expressed in yeast. Molecular and Biochemical Parasitology 1998, 94:205-214.
54. Cowman A.F., Morry M.J., Biggs B.A., Cross G.A., Foote S.J. Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proceedings of the National Academy of Sciences of the United States of America 1988, 85:9109-9113.
55. Cravo P., Figueiredo S., Nogueira F., Lopes D., Ferreira I.D., Ferreira C., Gil J.P., do Rosario V.E. High frequency of the genetic polymorphisms associated with sulfadoxine-pyrimethamine resistance, among Plasmodium falciparum isolates from Sao Tome and Principe, West Africa. Annals of Tropical Medicine and Parasitology 2004, 98:293-296.
56. Curtis J., Duraisingh M.T., Trigg J.K., Mbwana H., Warhurst D.C., Curtis C.F. Direct evidence that asparagine at position 108 of the Plasmodium falciparum dihydrofolate reductase is involved in resistance to antifolate drugs in Tanzania. Transactions of the Royal Society of Tropical Medicine and Hygiene 1996, 90:678-680.
57. Curtis J., Duraisingh M.T., Warhurst D.C. In vivo selection for a specific genotype of dihydropteroate synthetase of Plasmodium falciparum by pyrimethamine-sulfadoxine but not chlorproguanil-dapsone treatment. The Journal of Infectious Diseases 1998, 177:1429-1433.
58. Curtis J., Maxwell C.A., Msuya F.H., Mkongewa S., Alloueche A., Warhurst D.C. Mutations in dhfr in Plasmodium falciparum infections selected by chlorproguanil-dapsone treatment. The Journal of Infectious Diseases 2002, 186:1861-1864.
59. Darlow B., Vrbova H., Stace J., Heywood P., Aalpers M. Fansidar-resistant falciparum malaria in Papua New Guinea. Lancet 1980, 2:1243.
60. Das S., Chakraborty S.P., Tripathy S., Hati A.K., Roy S. Association between prevalence of pyrimethamine resistance and double mutation in pfdhfr gene in West Bengal, India. Asian Pacific Journal of Tropical Disease 2012, 2:31-35.
61. DeGowin R.L., Powell R.D. Drug-resistant falciparum malaria. Journal of Laboratory and Clinical Medicine 1964, 64:851-852.
62. Dicko A., Sagara I., Djimdé A.A., Toure S.O., Traore M., Dama S., Diallo A.I., Barry A., Dicko M., Coulibaly O.M., Rogier C., de Sousa A., Doumbo O.K. Molecular markers of resistance to sulphadoxine-pyrimethamine one year after implementation of intermittent preventive treatment of malaria in infants in Mali. Malaria Journal 2010, 9:9.
63. Diourté Y., Djimdé A., Doumbo O.K., Sagara I., Coulibaly Y., Dicko A., Diallo M., Diakite M., Cortese J.F., Plowe C.V. Pyrimethamine-sulfadoxine efficacy and selection for mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in Mali. The American Journal of Tropical Medicine and Hygiene 1999, 60:475-478.
64. Djaman A.J., Basco L.K., Mazabraud A. [Monitoring the chemoresistance of Plasmodium falciparum malaria in Yopougon (Abidjan): in vivo study of chloroquine sensitivity and evaluation of pyrimethamine resistance following the analysis of point mutation in the dihydrofolate reductase gene]. Sante 2002, 12:363-367.
65. Djimdé A.A., Dolo A., Ouattara A., Diakite S., Plowe C.V., Doumbo O.K. Molecular diagnosis of resistance to antimalarial drugs during epidemics and in war zones. The Journal of Infectious Diseases 2004, 190:853-855.
66. Djimdé A.A., Doumbo O.K., Cortese J.F., Kayentao K., Doumbo S., Diourté Y., Coulibaly D., Dicko A., Su X-Z., Nomura T., Fidock D.A., Wellems T.E., Plowe C.V. A molecular marker for chloroquine-resistant falciparum malaria. The New England Journal of Medicine 2001, 344:257-263.
67. Djimdé A.A., Doumbo O.K., Traore O., Guindo A.B., Kayentao K., Diourté Y., Niare-Doumbo S., Coulibaly D., Kone A.K., Cissoko Y., Tekete M., Fofana B., Dicko A., Diallo D.A., Wellems T.E., Kwiatkowski D., Plowe C.V. Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. The American Journal of Tropical Medicine and Hygiene 2003, 69:558-563.
68. Dlamini S.V., Beshir K., Sutherland C.J. Markers of anti-malarial drug resistance in Plasmodium falciparum isolates from Swaziland: identification of pfmdr1-86F in natural parasite isolates. Malaria Journal 2010, 9:68.
69. Doherty J.F., Sadiq A.D., Bayo L., Alloueche A., Olliaro P., Milligan P., von Seidlein L., Pinder M. A randomized safety and tolerability trial of artesunate plus sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone for the treatment of uncomplicated malaria in Gambian children. Transactions of the Royal Society of Tropical Medicine and Hygiene 1999, 93:543-546.
70. Dondorp A.M., Nosten F., Yi P., Das D., Phyo A.P., Tarning J., Lwin K.M., Ariey F., Hanpithakpong W., Lee S.J., Ringwald P., Silamut K., Imwong M., Chotivanich K., Lim P., Herdman T., An S.S., Yeung S., Singhasivanon P., Day N.P., Lindegardh N., Socheat D., White N.J. Artemisinin resistance in Plasmodium falciparum malaria. The New England Journal of Medicine 2009, 361:455-467.
71. Dorsey G., Dokomajilar C., Kiggundu M., Staedke S.G., Kamya M.R., Rosenthal P.J. Principal role of dihydropteroate synthase mutations in mediating resistance to sulfadoxine-pyrimethamine in single-drug and combination therapy of uncomplicated malaria in Uganda. The American Journal of Tropical Medicine and Hygiene 2004, 71:758-763.
72. Dorsey G., Vlahos J., Kamya M.R., Staedke S.G., Rosenthal P.J. Prevention of increasing rates of treatment failure by combining sulfadoxine-pyrimethamine with artesunate or amodiaquine for the sequential treatment of malaria. The Journal of Infectious Diseases 2003, 188:1231-1238.
73. Doumbo O.K., Kayentao K., Djimdé A., Cortese J.F., Diourté Y., Konare A., Kublin J.G., Plowe C.V. Rapid selection of Plasmodium falciparum dihydrofolate reductase mutants by pyrimethamine prophylaxis. The Journal of Infectious Diseases 2000, 182:993-996.
74. Duah, N.O., Quashie, N.B., Abuaku, B.K., Sebeny, P.J., Kronmann, K.C., Koram, K.A., 2012. Surveillance of molecular markers of Plasmodium falciparum resistance to sulphadoxine-pyrimethamine 5 years after the change of malaria treatment policy in Ghana. The American Journal of Tropical Medicine and Hygiene, in press.
75. Dunyo S., Ord R., Hallett R., Jawara M., Walraven G., Mesa E., Coleman R., Sowe M., Alexander N., Targett G.A., Pinder M., Sutherland C.J. Randomised trial of chloroquine/sulphadoxine-pyrimethamine in Gambian children with malaria: impact against multidrug-resistant P. falciparum. PLoS Clinical Trials 2006, 1:e14.
76. Dzinjalamala F.K., Macheso A., Kublin J.G., Taylor T.E., Barnes K.I., Molyneux M.E., Plowe C.V., Smith P.J. Blood folate concentrations and in vivo sulfadoxine-pyrimethamine failure in Malawian children with uncomplicated Plasmodium falciparum malaria. The American Journal of Tropical Medicine and Hygiene 2005, 72:267-672.
77. Eberl K.J., Jelinek T., Aida A.O., Peyerl-Hoffmann G., Heuschkel C., el Valy A.O., Christophel E.M. Prevalence of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum isolates from southern Mauritania. Tropical Medicine & International Health: TM & IH 2001, 6:756-760.
78. Eboumbou Moukoko E.C., Bogreau H., Briolant S., Pradines B., Rogier C. [Molecular markers of Plasmodium falciparum drug resistance]. Medecine Tropicale: revue du Corps de sante colonial 2009, 69:606-612.
79. Elbashir M.I., Adam I. Antimalarial drugs resistance in Sudan. Khartoum Medical Journal 2008, 1:7-11.
80. Enosse S., Magnussen P., Abacassamo F., Gomez-Olive X., Ronn A., Thompson R., Alifrangis M. Rapid increase of Plasmodium falciparum dhfr/dhps resistant haplotypes, after the adoption of sulphadoxine-pyrimethamine as first-line treatment in 2002, in southern Mozambique. Malaria Journal 2008, 7:115.
81. Eriksen J., Mwankusye S., Mduma S., Kitua A., Swedberg G., Tomson G., Gustafsson L.L., Warsame M. Patterns of resistance and DHFR/DHPS genotypes of Plasmodium falciparum in rural Tanzania prior to the adoption of sulfadoxine-pyrimethamine as first-line treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene 2004, 98:347-353.
82. Eriksen J., Mwankusye S., Mduma S., Veiga M.I., Kitua A., Tomson G., Petzold M.G., Swedberg G., Gustafsson L.L., Warsame M. Antimalarial resistance and DHFR/DHPS genotypes of Plasmodium falciparum three years after introduction of sulfadoxine-pyrimethamine and amodiaquine in rural Tanzania. Transactions of the Royal Society of Tropical Medicine and Hygiene 2008, 102:137-142.
83. Eskandarian A.A., Keshavarz H., Basco L.K., Mahboudi F. Do mutations in Plasmodium falciparum dihydropteroate synthase and dihydrofolate reductase confer resistance to sulfadoxine-pyrimethamine in Iran?. Transactions of the Royal Society of Tropical Medicine and Hygiene 2002, 96:96-98.
84. Faye B., Ndiaye M., Ndiaye J.L., Annie A., Tine R.C., Lo A.C., Sow D., de Sousa A., Gaye O. Prevalence of molecular markers of Plasmodium falciparum resistance to sulfadoxine-pyrimethamine during the intermittent preventive treatment in infants coupled with the expanded program immunization in Senegal. Parasitology Research 2011, 109:133-138.
85. Fernandes N.E., Cravo P., do Rosario V.E. [Sulfadoxine-pyrimethamine resistance in Maputo, Mozambique: presence of mutations in the dhfr and dhps genes of Plasmodium falciparum]. Revista da Sociedade Brasileira de Medicina Tropical 2007, 40:447-450.
86. Ferone R. Folate metabolism in malaria. Bulletin of the World Health Organization 1977, 55:291-298.
87. Figueiredo P., Benchimol C., Lopes D., Bernardino L., do Rosario V.E., Varandas L., Nogueira F. Prevalence of pfmdr1, pfcrt, pfdhfr and pfdhps mutations associated with drug resistance, in Luanda, Angola. Malaria Journal 2008, 7:236.
88. Foote S.J., Cowman A.F. The mode of action and the mechanism of resistance to antimalarial drugs. Acta Tropica 1994, 56:157-171.
89. Francis D., Nsobya S.L., Talisuna A., Yeka A., Kamya M.R., Machekano R., Dokomajilar C., Rosenthal P.J., Dorsey G. Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance. The Journal of Infectious Diseases 2006, 193:978-986.
90. Gasasira A.F., Kamya M.R., Ochong E.O., Vora N., Achan J., Charlebois E., Ruel T., Kateera F., Meya D.N., Havlir D., Rosenthal P.J., Dorsey G. Effect of trimethoprim-sulphamethoxazole on the risk of malaria in HIV-infected Ugandan children living in an area of widespread antifolate resistance. Malaria Journal 2010, 9:177.
91. Gatton M.L., Martin L.B., Cheng Q. Evolution of resistance to sulfadoxine-pyrimethamine in Plasmodium falciparum. Antimicrobial Agents and Chemotherapy 2004, 48:2116-2123.
92. Gebru-Woldearegai T., Hailu A., Grobusch M.P., Kun J.F. Molecular surveillance of mutations in dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum in Ethiopia. The American Journal of Tropical Medicine and Hygiene 2005, 73:1131-1134.
93. Gesase S., Gosling R.D., Hashim R., Ord R., Naidoo I., Madebe R., Mosha J.F., Joho A., Mandia V., Mrema H., Mapunda E., Savael Z., Lemnge M., Mosha F.W., Greenwood B., Roper C., Chandramohan D. High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at Codon 581. PLoS One 2009, 4:e4569.
94. Giraldo L.E., Acosta M.C., Labrada L.A., Praba A., Montenegro-James S., Saravia N.G., Krogstad D.J. Frequency of the Asn-108 and Thr-108 point mutations in the dihydrofolate reductase gene in Plasmodium falciparum from southwest Colombia. The American Journal of Tropical Medicine and Hygiene 1998, 59:124-128.
95. Greenwood B. The molecular epidemiology of malaria. Tropical Medicine & International Health: TM & IH 2002, 7:1012-1021.
96. Griffin J.T., Cairns M., Ghani A.C., Roper C., Schellenberg D., Carneiro I., Newman R.D., Grobusch M.P., Greenwood B., Chandramohan D., Gosling R.D. Protective efficacy of intermittent preventive treatment of malaria in infants (IPTi) using sulfadoxine-pyrimethamine and parasite resistance. PLoS One 2010, 5:e12618.
97. Grobusch M.P., Egan A., Gosling R.D., Newman R.D. Intermittent preventive therapy for malaria: progress and future directions. Current Opinion in Infectious Diseases 2007, 20:613-620.
98. Hamel M.J., Poe A., Bloland P., Mccollum A., Zhou Z., Shi Y.P., Ouma P., Otieno K., Vulule J., Escalante A., Udhayakumar V., Slutsker L. Dihydrofolate reductase I164L mutations in Plasmodium falciparum isolates: clinical outcome of 14 Kenyan adults infected with parasites harbouring the I164L mutation. Transactions of the Royal Society of Tropical Medicine and Hygiene 2008, 102:338-345.
99. Happi C.T., Gbotosho G.O., Folarin O.A., Akinboye D.O., Yusuf B.O., Ebong O.O., Sowunmi A., Kyle D.E., Milhous W., Wirth D.F., Oduola A.M. Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine-pyrimethamine resistance in malaria-infected patients from Nigeria. Acta Tropica 2005, 95:183-193.
100. Harinasuta T., Viravan C., Reid H.A. Sulphormethoxine in chloroquine-resistant falciparum malaria in Thailand. Lancet 1967, 1:1117-1119.
101. Harrington W.E., Mutabingwa T.K., Muehlenbachs A., Sorensen B., Bolla M.C., Fried M., Duffy P.E. Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:9027-9032.
102. Hastings M.D., Bates S.J., Blackstone E.A., Monks S.M., Mutabingwa T.K., Sibley C.H. Highly pyrimethamine-resistant alleles of dihydrofolate reductase in isolates of Plasmodium falciparum from Tanzania. Transactions of the Royal Society of Tropical Medicine and Hygiene 2002, 96:674-676.
103. Heidari A., Dittrich S., Jelinek T., Kheirandish A., Banihashemi K., Keshavarz H. Genotypes and in vivo resistance of Plasmodium falciparum isolates in an endemic region of Iran. Parasitology Research 2007, 100:589-592.
104. Huong N.M., Hewitt S., Davis T.M., Dao L.D., Toan T.Q., Kim T.B., Hanh N.T., Phuong V.N., Nhan D.H., Cong L.D. Resistance of Plasmodium falciparum to antimalarial drugs in a highly endemic area of southern Viet Nam: a study in vivo and in vitro. Transactions of the Royal Society of Tropical Medicine and Hygiene 2001, 95:325-329.
105. Hurly M.G. Potentiation of pyrimethamine by sulphadiazine in human malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene 1959, 53:412-413.
106. Hyde J.E. Antifolate resistance in Africa and the 164-dollar question. Transactions of the Royal Society of Tropical Medicine and Hygiene 2008, 102:301-303.
107. Hyde J.E. The dihydrofolate reductase-thymidylate synthetase gene in the drug resistance of malaria parasites. Pharmacology & Therapeutics 1990, 48:45-59.
108. Iriemenam N.C., Shah M., Gatei W., Van Eijk A.M., Ayisi J., Kariuki S., Vanden Eng J., Owino S.O., Lal A.A., Omosun Y.O., Otieno K., Desai M., Ter Kuile F.O., Nahlen B., Moore J., Hamel M.J., Ouma P., Slutsker L., Shi Y.P. Temporal trends of sulphadoxine-pyrimethamine (SP) drug-resistance molecular markers in Plasmodium falciparum parasites from pregnant women in western Kenya. Malaria Journal 2012, 11:134.
109. Iyer J.K., Milhous W.K., Cortese J.F., Kublin J.G., Plowe C.V. Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine. Lancet 2001, 358:1066-1067.
110. Jambou R., Legrand E., Niang M., Khim N., Lim P., Volney B., Ekala M.T., Bouchier C., Esterre P., Fandeur T. Resistance of Plasmodium falciparum field isolates to in vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 2005, 366:1960-1963.
111. Jafari S., le Bras J., Asmar M., Durand R. Molecular survey of Plasmodium falciparum resistance in south-eastern Iran. Annals of Tropical Medicine and Parasitology 2003, 97:119-124.
112. Jelinek T., Peyerl-Hoffmann G., Muhlberger N., Wichmann O., Wilhelm M., Schmider N., Grobusch M., von Sonnenburg F., Gascon J., Laferl H., Hatz C., Alifrangis M., Burchard G., Mcwhinney P., Schulze M., Kollaritsch H., da Cunha S., Beran J., Kern P., Gjorup I., Cuadros J. Molecular surveillance of drug resistance through imported isolates of Plasmodium falciparum in Europe. Malaria Journal 2002, 1:11.
113. Jelinek T., Ronn A.M., Lemnge M.M., Curtis J., Mhina J., Duraisingh M.T., Bygbjerg I.C., Warhurst D.C. Polymorphisms in the dihydrofolate reductase (DHFR) and dihydropteroate synthetase (DHPS) genes of Plasmodium falciparum and in vivo resistance to sulphadoxine/pyrimethamine in isolates from Tanzania. Tropical Medicine & International Health: TM & IH 1998, 3:605-609.
114. Jones S.A. Resistance of P. falciparum and P. malariae to pyrimethamine (daraprim) following mass treatment with this drug; a preliminary note. East African Medical Journal 1954, 31:47-49.
115. Jones S.A. Mass treatment with pyrimethamine; a study of resistance and cross resistance resulting from a field trial in the hyperendemic malarious area of Makueni, Kenya. September 1952-September 1953. Transactions of the Royal Society of Tropical Medicine and Hygiene 1958, 52:547-561.
116. Juliano J.J., Trottman P., Mwapasa V., Meshnick S.R. Detection of the dihydrofolate reductase-164L mutation in Plasmodium falciparum infections from Malawi by heteroduplex tracking assay. The American Journal of Tropical Medicine and Hygiene 2008, 78:892-894.
117. Karema C., Imwong M., Fanello C.I., Stepniewska K., Uwimana A., Nakeesathit S., Dondorp A., Day N.P., White N.J. Molecular correlates of high-level antifolate resistance in Rwandan children with Plasmodium falciparum malaria. Antimicrobial Agents and Chemotherapy 2010, 54:477-483.
118. Khalil I., Alifrangis M., Ronn A.M., Gabar H.A., Jelinek T., Satti G.M., Bygbjerg I.C. Pyrimethamine/sulfadoxine combination in the treatment of uncomplicated falciparum malaria: relation between dihydropteroate synthase/dihydrofolate reductase genotypes, sulfadoxine plasma levels, and treatment outcome. The American Journal of Tropical Medicine and Hygiene 2002, 67:225-229.
119. Kinzer M.H., Chand K., Basri H., Lederman E.R., Susanti A.I., Elyazar I., Taleo G., Rogers W.O., Bangs M.J., Maguire J.D. Active case detection, treatment of falciparum malaria with combined chloroquine and sulphadoxine/pyrimethamine and vivax malaria with chloroquine and molecular markers of anti-malarial resistance in the Republic of Vanuatu. Malaria Journal 2010, 9:89.
120. Kublin J.G., Cortese J.F., Njunju E.M., Mukadam R.A., Wirima J.J., Kazembe P.N., Djimdé A.A., Kouriba B., Taylor T.E., Plowe C.V. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. The Journal of Infectious Diseases 2003, 187:1870-1875.
121. Kublin J.G., Dzinjalamala F.K., Kamwendo D.D., Malkin E.M., Cortese J.F., Martino L.M., Mukadam R.A., Rogerson S.J., Lescano A.G., Molyneux M.E., Winstanley P.A., Chimpeni P., Taylor T.E., Plowe C.V. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. The Journal of Infectious Diseases 2002, 185:380-388.
122. Kublin J.G., Witzig R.S., Shankar A.H., Zurita J.Q., Gilman R.H., Guarda J.A., Cortese J.F., Plowe C.V. Molecular assays for surveillance of antifolate-resistant malaria. Lancet 1998, 351:1629-1630.
123. Kun J.F., Lehman L.G., Lell B., Schmidt-Ott R., Kremsner P.G. Low-dose treatment with sulfadoxine-pyrimethamine combinations selects for drug-resistant Plasmodium falciparum strains. Antimicrobial Agents and Chemotherapy 1999, 43:2205-2208.
124. Kyabayinze D., Cattamanchi A., Kamya M.R., Rosenthal P.J., Dorsey G. Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with falciparum malaria. The American Journal of Tropical Medicine and Hygiene 2003, 69:247-252.
125. Labbe A.C., Patel S., Crandall I., Kain K.C. A molecular surveillance system for global patterns of drug resistance in imported malaria. Emerging Infectious Diseases 2003, 9:33-36.
126. Laxminarayan R., Bhutta Z.A., Duse A., Jenkins P., O'brien T., Okeke I.N., Pabelo-Mendez A. Drug resistance. Disease Control Priorities in Developing Countries 2006, Oxford University Press, New York. second ed. D.T. Jamison, J.G. Breman, A.R. Measham, G. Alleyne, M. Claeson, D.B. Evans, P. Jha (Eds.).
127. Liang A.B. Antimalarial effect of sulphorthodimethoxine (Fanasil). British Medical Journal 1964, 2:1439-1440.
128. Liang A.B. Treatment of acute falciparum malaria with sulphorthodimethoxine (Fanasil). British Medical Journal 1965, 1:905-907.
129. Laing A.B. Hospital and field trials of sulformethoxine with pyrimethamine against Malaysian strains of Plasmodium falciparum and P. vivax. The Medical Journal of Malaya 1968, 23:5-19.
130. Laing A.B. Studies on the chemotherapy of malaria. I. The treatment of overt falciparum malaria with potentiating combinations of pyrimethamine and sulphormethoxine or dapsone in The Gambia. Transactions of the Royal Society of Tropical Medicine and Hygiene 1970, 64:562-568.
131. Londono B.L., Eisele T.P., Keating J., Bennett A., Chattopadhyay C., Heyliger G., Mack B., Rawson I., Vely J.F., Désinor O., Krogstad D.J. Chloroquine-resistant haplotype Plasmodium falciparum parasites, Haiti. Emerging Infectious Diseases 2009, 15:735-740.
132. Londono-Renteria B., Eisele T.P., Keating J., Bennett A., Krogstad D.J. Genetic diversity in the merozoite surface protein 1 and 2 genes of Plasmodium falciparum from the Artibonite Valley of Haiti. Acta Tropica 2012, 121:6-12.
133. Lumb V., Das M.K., Mittra P., Ahmed A., Kumar M., Kaur P., Dash A.P., Singh S.S., Sharma Y.D. Emergence of an unusual sulfadoxine-pyrimethamine resistance pattern and a novel K540N mutation in dihydropteroate synthetase in Plasmodium falciparum isolates obtained from Car Nicobar Island, India, after the 2004 Tsunami. The Journal of Infectious Diseases 2009, 199:1064-1073.
134. Lynch C., Pearce R., Pota H., Cox J., Abeku T.A., Rwakimari J., Naidoo I., Tibenderana J., Roper C. Emergence of a dhfr mutation conferring high-level drug resistance in Plasmodium falciparum populations from southwest Uganda. The Journal of Infectious Diseases 2008, 197:1598-1604.
135. Maïga O., Djimdé A.A., Hubert V., Renard E., Aubouy A., Kironde F., Nsimba B., Koram K., Doumbo O.K., Le Bras J., Clain J. A shared Asian origin of the triple-mutant dhfr allele in Plasmodium falciparum from sites across Africa. The Journal of Infectious Diseases 2007, 196:165-172.
136. Malisa A., Pearce R., Abdullah S., Mutayoba B., Mshinda H., Kachur P., Bloland P., Roper C. Molecular monitoring of resistant dhfr and dhps allelic haplotypes in Morogoro and Mvomero districts in south eastern Tanzania. African Health Sciences 2011, 11:142-150.
137. Malisa A.L., Pearce R.J., Abdulla S., Mshinda H., Kachur P.S., Bloland P., Roper C. Drug coverage in treatment of malaria and the consequences for resistance evolution - evidence from the use of sulphadoxine/pyrimethamine. Malaria Journal 2010, 9:190.
138. Marfurt J., Smith T.A., Hastings I.M., Muller I., Sie A., Oa O., Baisor M., Reeder J.C., Beck H.P., Genton B. Plasmodium falciparum resistance to anti-malarial drugs in Papua New Guinea: evaluation of a community-based approach for the molecular monitoring of resistance. Malaria Journal 2010, 9:8.
139. Marks F., Evans J., Meyer C.G., Browne E.N., Flessner C., von Kalckreuth V., Eggelte T.A., Horstmann R.D., May J. High prevalence of markers for sulfadoxine and pyrimethamine resistance in Plasmodium falciparum in the absence of drug pressure in the Ashanti region of Ghana. Antimicrobial Agents and Chemotherapy 2005, 49:1101-1105.
140. Marma A.S., Mita T., Eto H., Tsukahara T., Sarker S., Endo H. High prevalence of sulfadoxine/pyrimethamine resistance alleles in Plasmodium falciparum parasites from Bangladesh. Parasitology International 2010, 59:178-182.
141. Masimirembwa C.M., Phuong-Dung N., Phuc B.Q., Duc-Dao L., Sy N.D., Skold O., Swedberg G. Molecular epidemiology of Plasmodium falciparum antifolate resistance in Vietnam: genotyping for resistance variants of dihydropteroate synthase and dihydrofolate reductase. International Journal of Antimicrobial Agents 1999, 12:203-211.
142. Mawili-Mboumba D.P., Ekala M.T., Lekoulou F., Ntoumi F. Molecular analysis of DHFR and DHPS genes in P. falciparum clinical isolates from the Haut-Ogooue region in Gabon. Acta Tropica 2001, 78:231-240.
143. Mayers D.L., Lerner S.A., Ouellette M., Sobel J.D. Antimicrobial Drug Resistance: Mechanisms of Drug Resistance 2009, Humana Press.
144. Mayor A., Serra-Casas E., Sanz S., Aponte J.J., Macete E., Mandomando I., Puyol L., Berzosa P., Dobano C., Aide P., Sacarlal J., Benito A., Alonso P., Menendez C. Molecular markers of resistance to sulfadoxine-pyrimethamine during intermittent preventive treatment for malaria in Mozambican infants. The Journal of Infectious Diseases 2008, 197:1737-1742.
145. Mbacham W.F., Evehe M.S., Netongo P.M., Ateh I.A., Mimche P.N., Ajua A., Nji A.M., Irenee D., Echouffo-Tcheugui J.B., Tawe B., Hallett R., Roper C., Targett G., Greenwood B. Efficacy of amodiaquine, sulphadoxine-pyrimethamine and their combination for the treatment of uncomplicated Plasmodium falciparum malaria in children in Cameroon at the time of policy change to artemisinin-based combination therapy. Malaria Journal 2010, 9:34.
146. Mbacham W.F., Evehe M.S.B., Netongo P.M., Ali I.M., Nfor N.E., Akaragwe A.I., Mimche P.N., Nji A. Mutations within folate metabolising genes of Plasmodium falciparum in Cameroon. African Journal of Biotechnology 2009, 8:4749-4754.
147. Mbaisi A., Liyala P., Eyase F., Achilla R., Akala H., Wangui J., Mwangi J., Osuna F., Alam U., Smoak B.L., Davis J.M., Kyle D.E., Coldren R.L., Mason C., Waters N.C. Drug susceptibility and genetic evaluation of Plasmodium falciparum isolates obtained in four distinct geographical regions of Kenya. Antimicrobial Agents and Chemotherapy 2004, 48:3598-3601.
148. Mccollum A.M., Basco L.K., Tahar R., Udhayakumar V., Escalante A.A. Hitchhiking and selective sweeps of Plasmodium falciparum sulfadoxine and pyrimethamine resistance alleles in a population from central Africa. Antimicrobial Agents and Chemotherapy 2008, 52:4089-4097.
149. Mccollum A.M., Mueller K., Villegas L., Udhayakumar V., Escalante A.A. Common origin and fixation of Plasmodium falciparum dhfr and dhps mutations associated with sulfadoxine-pyrimethamine resistance in a low-transmission area in South America. Antimicrobial Agents and Chemotherapy 2007, 51:2085-2091.
150. Mccollum A.M., Poe A.C., Hamel M., Huber C., Zhou Z., Shi Y.P., Ouma P., Vulule J., Bloland P., Slutsker L., Barnwell J.W., Udhayakumar V., Escalante A.A. Antifolate resistance in Plasmodium falciparum: multiple origins and identification of novel dhfr alleles. The Journal of Infectious Diseases 2006, 194:189-197.
151. Mccollum A.M., Schneider K.A., Griffing S.M., Zhou Z., Kariuki S., Ter-Kuile F., Shi Y.P., Slutsker L., Lal A.A., Udhayakumar V., Escalante A.A. Differences in selective pressure on dhps and dhfr drug resistant mutations in western Kenya. Malaria Journal 2012, 11:77.
152. Menard D., Andriantsoanirina V., Jahevitra M., Barnadas C., Tichit M., Bouchier C., Hopkins Sibley C. Dihydrofolate reductase I164L mutation in Plasmodium falciparum, Madagascar. Emerging Infectious Diseases 2008, 14:1166-1167.
153. Menard D., Djalle D., Yapou F., Manirakiza A., Talarmin A. Frequency distribution of antimalarial drug-resistant alleles among isolates of Plasmodium falciparum in Bangui, Central African Republic. The American Journal of Tropical Medicine and Hygiene 2006, 74:205-210.
154. Mendez F., Munoz A., Carrasquilla G., Jurado D., Arevalo-Herrera M., Cortese J.F., Plowe C.V. Determinants of treatment response to sulfadoxine-pyrimethamine and subsequent transmission potential in falciparum malaria. American Journal of Epidemiology 2002, 156:230-238.
155. Menegon M., Talha A.A., Severini C., Elbushra S.M., Mohamedani A.A., Malik E.M., Mohamed T.A., Wernsdorfer W.H., Majori G., Nour B.Y. Frequency distribution of antimalarial drug resistance alleles among Plasmodium falciparum isolates from Gezira State, central Sudan, and Gedarif State, eastern Sudan. The American Journal of Tropical Medicine and Hygiene 2010, 83:250-257.
156. Menegon M., Pearce R.J., Inojosa W.O., Pisani V., Abel P.M., Matondo A., Bisoffi Z., Majori G., Ord R., Warhurst D.C., Roper C., Severini C. Monitoring for multidrug-resistant Plasmodium falciparum isolates and analysis of pyrimethamine resistance evolution in Uige province, Angola. Tropical Medicine & International Health: TM & IH 2009, 14:1251-1257.
157. Menemedengue V., Sahnouni K., Basco L., Tahar R. Molecular epidemiology of malaria in Cameroon. XXX. sequence analysis of Plasmodium falciparum ATPase 6, dihydrofolate reductase, and dihydropteroate synthase resistance markers in clinical isolates from children treated with an artesunate-sulfadoxine-pyrimethamine combination. The American Journal of Tropical Medicine and Hygiene 2011, 85:22-25.
158. Menendez C., Serra-Casas E., Scahill M.D., Sanz S., Nhabomba A., Bardaji A., Sigauque B., Cistero P., Mandomando I., Dobano C., Alonso P.L., Mayor A. HIV and placental infection modulate the appearance of drug-resistant Plasmodium falciparum in pregnant women who receive intermittent preventive treatment. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2011, 52:41-48.
159. Mharakurwa S., Kumwenda T., Mkulama M.A., Musapa M., Chishimba S., Shiff C.J., Sullivan D.J., Thuma P.E., Liu K., Agre P. Malaria antifolate resistance with contrasting Plasmodium falciparum dihydrofolate reductase (DHFR) polymorphisms in humans and Anopheles mosquitoes. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:18796-18801.
160. Mita T., Tanabe K., Kita K. Spread and evolution of Plasmodium falciparum drug resistance. Parasitology International 2009, 58:201-209.
161. Mita T., Tanabe K., Takahashi N., Culleton R., Ndounga M., Dzodzomenyo M., Akhwale W.S., Kaneko A., Kobayakawa T. Indigenous evolution of Plasmodium falciparum pyrimethamine resistance multiple times in Africa. The Journal of Antimicrobial Chemotherapy 2009, 63:252-255.
162. Mita T., Tanabe K., Takahashi N., Tsukahara T., Eto H., Dysoley L., Ohmae H., Kita K., Krudsood S., Looareesuwan S., Kaneko A., Bjorkman A., Kobayakawa T. Independent evolution of pyrimethamine resistance in Plasmodium falciparum isolates in Melanesia. Antimicrobial Agents and Chemotherapy 2007, 51:1071-1077.
163. Mixson-Hayden T., Jain V., McCollum A.M., Poe A., Nagpal A.C., Dash A.P., Stiles J.K., Udhayakumar V., Singh N. Evidence of selective sweeps in genes conferring resistance to chloroquine and pyrimethamine in Plasmodium falciparum isolates in India. Antimicrobial Agents and Chemotherapy 2010, 54:997-1006.
164. Mlambo G., Sullivan D., Mutambu S.L., Soko W., Mbedzi J., Chivenga J., Gemperli A., Kumar N. High prevalence of molecular markers for resistance to chloroquine and pyrimethamine in Plasmodium falciparum from Zimbabwe. Parasitology Research 2007, 101:1147-1151.
165. Mockenhaupt F.P., Bedu-Addo G., Eggelte T.A., Hommerich L., Holmberg V., von Oertzen C., Bienzle U. Rapid increase in the prevalence of sulfadoxine-pyrimethamine resistance among Plasmodium falciparum isolated from pregnant women in Ghana. The Journal of Infectious Diseases 2008, 198:1545-1549.
166. Mockenhaupt F.P., Bedu-Addo G., Junge C., Hommerich L., Eggelte T.A., Bienzle U. Markers of sulfadoxine-pyrimethamine-resistant Plasmodium falciparum in placenta and circulation of pregnant women. Antimicrobial Agents and Chemotherapy 2007, 51:332-334.
167. Mockenhaupt F.P., Eggelte T.A., Böhme T., Thompson W.N., Bienzle U. Plasmodium falciparum dihydrofolate reductase alleles and pyrimethamine use in pregnant Ghanaian women. The American Journal of Tropical Medicine and Hygiene 2001, 65:21-26.
168. Mockenhaupt F.P., Teun Bousema J., Eggelte T.A., Schreiber J., Ehrhardt S., Wassilew N., Otchwemah R.N., Sauerwein R.W., Bienzle U. Plasmodium falciparum dhfr but not dhps mutations associated with sulphadoxine-pyrimethamine treatment failure and gametocyte carriage in northern Ghana. Tropical Medicine & International Health: TM & IH 2005, 10:901-908.
169. Mombo-Ngoma G., Oyakhirome S., Ord R., Gabor J.J., Greutelaers K.C., Profanter K., Greutelaers B., Kurth F., Lell B., Kun J.F., Issifou S., Roper C., Kremsner P.G., Grobusch M.P. High prevalence of dhfr triple mutant and correlation with high rates of sulphadoxine-pyrimethamine treatment failures in vivo in Gabonese children. Malaria Journal 2011, 10:123.
170. Mubjer R., Adeel A., Chance M., Hassan A. Molecular markers of anti-malarial drug resistance in Lahj Governorate, Yemen: baseline data and implications. Malaria Journal 2011, 10:245.
171. Mugittu K., Ndejembi M., Malisa A., Lemnge M., Premji Z., Mwita A., Nkya W., Kataraihya J., Abdulla S., Beck H.P., Mshinda H. Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance. The American Journal of Tropical Medicine and Hygiene 2004, 71:696-702.
172. Nagesha H.S., Din S., Casey G.J., Susanti A.I., Fryauff D.J., Reeder J.C., Cowman A.F. Mutations in the pfmdr1, dhfr and dhps genes of Plasmodium falciparum are associated with in vivo drug resistance in West Papua, Indonesia. Transactions of the Royal Society of Tropical Medicine and Hygiene 2001, 95:43-49.
173. Naidoo I., Roper C. Following the path of most resistance: dhps K540E dispersal in African Plasmodium falciparum. Trends in Parasitology 2010, 26:447-456.
174. Nair S., Williams J.T., Brockman A., Paiphun L., Mayxay M., Newton P.N., Guthmann J.P., Smithuis F.M., Hien T.T., White N.J., Nosten F., Anderson T.J. A selective sweep driven by pyrimethamine treatment in southeast asian malaria parasites. Molecular Biology and Evolution 2003, 20:1526-1536.
175. Nash D., Nair S., Mayxay M., Newton P.N., Guthmann J.P., Nosten F., Anderson T.J. Selection strength and hitchhiking around two anti-malarial resistance genes. Proceedings. Biological Sciences/The Royal Society 2005, 272:1153-1161.
176. Ndiaye D., Daily J.P., Sarr O., Ndir O., Gaye O., Mboup S., Wirth D.F. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase genes in Senegal. Tropical Medicine & International Health: TM & IH 2005, 10:1176-1179.
177. Ndounga M., Tahar R., Basco L.K., Casimiro P.N., Malonga D.A., Ntoumi F. Therapeutic efficacy of sulfadoxine-pyrimethamine and the prevalence of molecular markers of resistance in under 5-year olds in Brazzaville, Congo. Tropical Medicine & International Health: TM & IH 2007, 12:1164-1171.
178. Ngo T., Duraisingh M., Reed M., Hipgrave D., Biggs B., Cowman A.F. Analysis of pfcrt, pfmdr1, dhfr, and dhps mutations and drug sensitivities in Plasmodium falciparum isolates from patients in Vietnam before and after treatment with artemisinin. The American Journal of Tropical Medicine and Hygiene 2003, 68:350-356.
179. Nguyen-Dinh P., Zevallos-Ipenza A., Magloire R. Plasmodium falciparum in Haiti: susceptibility to pyrimethamine and sulfadoxine-pyrimethamine. Bulletin of the World Health Organization 1984, 162:623-626.
180. Nkhoma S., Molyneux M., Ward S. Molecular surveillance for drug-resistant Plasmodium falciparum malaria in Malawi. Acta Tropica 2007, 102:138-142.
181. Nurse G.T. Fansidar-resistant falciparum malaria in Papua New Guinea. Lancet 1981, 1:36-37.
182. Nzila-Mounda A., Mberu E.K., Sibley C.H., Plowe C.V., Winstanley P.A., Watkins W.M. Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain. Antimicrobial Agents and Chemotherapy 1998, 42:164-169.
183. Nzila A.M., Mberu E.K., Sulo J., Dayo H., Winstanley P.A., Sibley C.H., Watkins W.M. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Antimicrobial Agents and Chemotherapy 2000, 44:991-996.
184. Nzunza R., Waters N.C. A Comparison of the chloroquine and sulfadoxine/pyrimethamine molecular resistance marker patterns between coastal and western Kenya. International Journal of Infectious Diseases 2008, 12(Suppl. 1):e312.
185. Ochong E., Bell D.J., Johnson D.J., D'alessandro U., Mulenga M., Muangnoicharoen S., Van Geertruyden J.P., Winstanley P.A., Bray P.G., Ward S.A., Owen A. Plasmodium falciparum strains harbouring dihydrofolate reductase with the I164L mutation are absent in Malawi and Zambia even under antifolate drug pressure. Antimicrobial Agents and Chemotherapy 2008, 52:3883-3888.
186. Ochong E., Nzila A., Kimani S., Kokwaro G., Mutabingwa T., Watkins W., Marsh K. Molecular monitoring of the Leu-164 mutation of dihydrofolate reductase in a highly sulfadoxine/pyrimethamine-resistant area in Africa. Malaria Journal 2003, 2:46.
187. Omar S.A., Adagu I.S., Gump D.W., Ndaru N.P., Warhurst D.C. Plasmodium falciparum in Kenya: high prevalence of drug-resistance-associated polymorphisms in hospital admissions with severe malaria in an epidemic area. Annals of Tropical Medicine and Parasitology 2001, 95:661-669.
188. Omar S.A., Adagu I.S., Warhurst D.C. Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine-pyrimethamine treatment failure?. Transactions of the Royal Society of Tropical Medicine and Hygiene 2001, 95:315-319.
189. Ouattara L., Bla K.B., Assi S.B., Yavo W., Djaman A.J. PFCRT and DHFR-TS sequences for monitoring drug resistance in Adzopé area of Côte d'Ivoire after the withdrawal of chloroquine and pyrimethamine. Tropical Journal of Pharmaceutical Research 2010, 9:565-572.
190. Owusu-Agyei S., Asante K.P., Adjuik M., Adjei G., Awini E., Adams M., Newton S., Dosoo D., Dery D., Agyeman-Budu A., Gyapong J., Greenwood B., Chandramohan D. Epidemiology of malaria in the forest-savanna transitional zone of Ghana. Malaria Journal 2009, 8:220.
191. Pearce R., Malisa A., Kachur S.P., Barnes K., Sharp B., Roper C. Reduced variation around drug-resistant dhfr alleles in African Plasmodium falciparum. Molecular Biology and Evolution 2005, 22:1834-1844.
192. Pearce R.J., Drakeley C., Chandramohan D., Mosha F., Roper C. Molecular determination of point mutation haplotypes in the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum in three districts of northern Tanzania. Antimicrobial Agents and Chemotherapy 2003, 47:1347-1354.
193. Pearce R.J., Pota H., Evehe M.S., Ba El H., Mombo-Ngoma G., Malisa A.L., Ord R., Inojosa W., Matondo A., Diallo D.A., Mbacham W., Van Den Broek I.V., Swarthout T.D., Getachew A., Dejene S., Grobusch M.P., Njie F., Dunyo S., Kweku M., Owusu-Agyei S., Chandramohan D., Bonnet M., Guthmann J.P., Clarke S., Barnes K.I., Streat E., Katokele S.T., Uusiku P., Agboghoroma C.O., Elegba O.Y., Cisse B., Ie A.E., Giha H.A., Kachur S.P., Lynch C., Rwakimari J.B., Chanda P., Hawela M., Sharp B., Naidoo I., Roper C. Multiple origins and regional dispersal of resistant dhps in African Plasmodium falciparum malaria. PLoS Medicine 2009, 6:e1000055.
194. Peters P.J., Thigpen M.C., Parise M.E., Newman R.D. Safety and toxicity of sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment. Drug Safety: An International Journal of Medical Toxicology and Drug Experience 2007, 30:481-501.
195. Peters W. Chemotherapy and Drug Resistance in Malaria 1987, Academic Press, London.
196. Peterson D.S., Walliker D., Wellems T.E. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proceedings of the National Academy of Sciences of the United States of America 1988, 85:9114-9118.
197. Phuc B.Q., Caruana S.R., Cowman A.F., Biggs B.A., Thanh N.V., Tien N.T., Thuan Le K. Prevalence of polymorphisms in DHFR, DHPS, PFMDR1 and PFCRT genes of Plasmodium falciparum isolates in Quang Tri Province, Vietnam. The Southeast Asian Journal of Tropical Medicine and Public Health 2008, 39:959-962.
198. Picot S., Olliaro P., de Monbrison F., Bienvenu A-L., Price R., Ringwald P. A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malaria Journal 2009, 8:89.
199. Plowe C.V. Folate antagonists and mechanisms of resistance. Antimalarial Chemotherapy: Mechanisms of Action, Resistance, and New Directions in Drug Discovery 2001, 173-190. Humana Press, Totowa, New York. P.J. Rosenthal (Ed.).
200. Plowe C.V. Monitoring antimalarial drug resistance: making the most of the tools at hand. The Journal of Experimental Biology 2003, 206:3745-3752.
201. Plowe C.V. Antimalarial drug resistance in Africa: strategies for monitoring and deterrence. Current Topics in Microbiology and Immunology 2005, 295:55-79.
202. Plowe C.V. The evolution of drug-resistant malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene 2009, 103(Suppl. 1):S11-S14.
203. Plowe C.V., Cortese J.F., Djimdé A., Nwanyanwu O.C., Watkins W.M., Winstanley P.A., Estrada-Franco J.G., Mollinedo R.E., Avila J.C., Cespedes J.L., Carter D., Doumbo O.K. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. The Journal of Infectious Diseases 1997, 176:1590-1596.
204. Plowe C.V., Djimdé A., Bouare M., Doumbo O., Wellems T.E. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. The American Journal of Tropical Medicine and Hygiene 1995, 52:565-568.
205. Plowe C.V., Djimdé A., Wellems T.E., Diop S., Kouriba B., Doumbo O.K. Community pyrimethamine-sulfadoxine use and prevalence of resistant Plasmodium falciparum genotypes in Mali: a model for deterring resistance. The American Journal of Tropical Medicine and Hygiene 1996, 55:467-471.
206. Plowe C.V., Kublin J.G., Doumbo O.K. P. falciparum dihydrofolate reductase and dihydropteroate synthase mutations: epidemiology and role in clinical resistance to antifolates. Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy 1998, 1:389-396.
207. Rallón N.I., Osorio L.E., Giraldo L.E. Lack of an association between the ASN-108 mutation in the dihydrofolate reductase gene and in vivo resistance to sulfadoxine/pyrimethamine in Plasmodium falciparum. The American Journal of Tropical Medicine and Hygiene 1999, 61:245-248.
208. Raman J., Little F., Roper C., Kleinschmidt I., Cassam Y., Maharaj R., Barnes K.I. Five years of large-scale dhfr and dhps mutation surveillance following the phased implementation of artesunate plus sulfadoxine-pyrimethamine in Maputo Province, Southern Mozambique. The American Journal of Tropical Medicine and Hygiene 2010, 82:788-794.
209. Randrianarivelojosia M., Ariey F., Raharimalala L.A., Parzy D., Rogier C., Jambou R. Current absence of pyrimethamine resistance of Plasmodium falciparum in Madagascar. Transactions of the Royal Society of Tropical Medicine and Hygiene 2002, 96:557-559.
210. Ranford-Cartwright L.C., Johnston K.L., Abdel-Muhsin A.M., Khan B.K., Babiker H.A. Critical comparison of molecular genotyping methods for detection of drug-resistant Plasmodium falciparum. Transactions of the Royal Society of Tropical Medicine and Hygiene 2002, 96:568-572.
211. Ranjitkar S., Schousboe M.L., Thomsen T.T., Adhikari M., Kapel C.M., Bygbjerg I.C., Alifrangis M. Prevalence of molecular markers of anti-malarial drug resistance in Plasmodium vivax and Plasmodium falciparum in two districts of Nepal. Malaria Journal 2011, 10:75.
212. Reeder J.C., Rieckmann K.H., Genton B., Lorry K., Wines B., Cowman A.F. Point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes and in vitro susceptibility to pyrimethamine and cycloguanil of Plasmodium falciparum isolates from Papua New Guinea. The American Journal of Tropical Medicine and Hygiene 1996, 55:209-213.
213. Richards W.H. Antimalarial activity of sulphonamides and a sulphone, singly and in combination with pyrimethamine, against drug resistant and normal strains of laboratory plasmodia. Nature 1966, 212:1494-1495.
214. Rønn A.M., Msangeni H.A., Mhina J., Wernsdorfer W.H., Bygbjerg I.C. High level of resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine in children in Tanzania. Transactions of the Royal Society of Tropical Medicine and Hygiene 1996, 90:179-181.
215. Roper C., Pearce R., Bredenkamp B., Gumede J., Drakeley C., Mosha F., Chandramohan D., Sharp B. Antifolate antimalarial resistance in southeast Africa: a population-based analysis. Lancet 2003, 361:1174-1181.
216. Roper C., Pearce R., Nair S., Sharp B., Nosten F., Anderson T. Intercontinental spread of pyrimethamine-resistant malaria. Science 2004, 305:1124.
217. Saha P., Guha S.K., Das S., Mullick S., Ganguly S., Biswas A., Bera D.K., Chattopadhyay G., Das M., Kundu P.K., Ray K., Maji A.K. Comparative efficacies of artemisinin combination therapies in Plasmodium falciparum malaria and polymorphism of pfATPase6, pfcrt, pfdhfr, and pfdhps Genes in Tea Gardens of Jalpaiguri District, India. Antimicrobial Agents and Chemotherapy 2012, 56:2511-2517.
218. Salgueiro P., Vicente J.L., Ferreira C., Teofilo V., Galvao A., do Rosario V.E., Cravo P., Pinto J. Tracing the origins and signatures of selection of antifolate resistance in island populations of Plasmodium falciparum. BMC Infectious Diseases 2010, 10:163.
219. Schönfeld M., Barreto Miranda I., Schunk M., Maduhu I., Maboko L., Hoelscher M., Berens-Riha N., Kitua A., Löscher T. Molecular surveillance of drug-resistance associated mutations of Plasmodium falciparum in south-west Tanzania. Malaria Journal 2007, 6:2.
220. Sendagire H., Kaddumukasa M., Ndagire D., Aguttu C., Nassejje M., Pettersson M., Swedberg G., Kironde F. Rapid increase in resistance of Plasmodium falciparum to chloroquine-Fansidar in Uganda and the potential of amodiaquine-Fansidar as a better alternative. Acta Tropica 2005, 95:172-182.
221. Sendagire H., Kyabayinze D., Swedberg G., Kironde F. Plasmodium falciparum: higher incidence of molecular resistance markers for sulphadoxine than for pyrimethamine in Kasangati, Uganda. Tropical Medicine & International Health: TM & IH 2005, 10:537-543.
222. Sibley C.H., Hyde J.E., Sims P.F.G., Plowe C.V., Kublin J.G., Mberu E.K., Cowman A.F., Winstanley P.A., Watkins W.M., Nzila A.M. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next?. Trends in Parasitology 2001, 17:582-588.
223. Sibley C.H., Ringwald P. A database of antimalarial drug resistance. Malaria Journal 2006, 5:48.
224. Sirawaraporn W., Sathitkul T., Sirawaraporn R., Yuthavong Y., Santi D.V. Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:1124-1129.
225. Smith J.M., Haigh J. The hitch-hiking effect of a favourable gene. Genetical Research 1974, 23:23-35.
226. Spalding M.D., Eyase F.L., Akala H.M., Bedno S.A., Prigge S.T., Coldren R.L., Moss W.J., Waters N.C. Increased prevalence of the pfdhfr/pfdhps quintuple mutant and rapid emergence of pfdhps resistance mutations at codons 581 and 613 in Kisumu, Kenya. Malaria Journal 2010, 9:338.
227. Sridaran S., Mcclintock S., Syphard L., Herman K., Barnwell J., Udhayakumar V. Anti-folate drug resistance in Africa: meta-analysis of reported dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) mutant genotype frequencies in African Plasmodium falciparum parasite populations. Malaria Journal 2010, 9:247.
228. Staedke S.G., Sendagire H., Lamola S., Kamya M.R., Dorsey G., Rosenthal P.J. Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda. Tropical Medicine & International Health: TM & IH 2004, 9:624-629.
229. Su X., Ferdig M.T., Huang Y., Huynh C.Q., Liu A., You J., Wootton J.C., Wellems T.E. A genetic map and recombination parameters of the human malaria parasite Plasmodium falciparum. Science 1999, 286:1351-1353.
230. Su X-Z., Wootton J.C. Selective sweeps in human malaria parasites. Evolution of Virulence in Eukaryotic Microbes 2012, 124-142. John Wiley & Sons, New Jersy. L.D. Sibley, B.J. Howlett, J. Heitman (Eds.).
231. Swarthout T.D., Van Den Broek I.V., Kayembe G., Montgomery J., Pota H., Roper C. Artesunate+amodiaquine and artesunate+sulphadoxine-pyrimethamine for treatment of uncomplicated malaria in Democratic Republic of Congo: a clinical trial with determination of sulphadoxine and pyrimethamine-resistant haplotypes. Tropical Medicine & International Health: TM & IH 2006, 11:1503-1511.
232. Syafruddin D., Asih P.B., Aggarwal S.L., Shankar A.H. Frequency distribution of antimalarial drug-resistant alleles among isolates of Plasmodium falciparum in Purworejo district, Central Java Province, Indonesia. The American Journal of Tropical Medicine and Hygiene 2003, 69:614-620.
233. Syafruddin D., Asih P.B., Casey G.J., Maguire J., Baird J.K., Nagesha H.S., Cowman A.F., Reeder J.C. Molecular epidemiology of Plasmodium falciparum resistance to antimalarial drugs in Indonesia. The American Journal of Tropical Medicine and Hygiene 2005, 72:174-781.
234. Tahar R., Basco L.K. Molecular epidemiology of malaria in Cameroon. XXII. Geographic mapping and distribution of Plasmodium falciparum dihydrofolate reductase (dhfr) mutant alleles. The American Journal of Tropical Medicine and Hygiene 2006, 75:396-401.
235. Tahar R., Basco L.K. Molecular epidemiology of malaria in Cameroon. XXVII. Clinical and parasitological response to sulfadoxine-pyrimethamine treatment and Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase alleles in Cameroonian children. Acta Tropica 2007, 103:81-89.
236. Talisuna A.O., Bloland P., D'alessandro U. History, dynamics, and public health importance of malaria parasite resistance. Clinical Microbiology Reviews 2004, 17:235-254.
237. Talisuna A.O., Langi P., Mutabingwa T.K., Watkins W., Van Marck E., Egwang T.G., D'alessandro U. Population-based validation of dihydrofolate reductase gene mutations for the prediction of sulfadoxine-pyrimethamine resistance in Uganda. Transactions of the Royal Society of Tropical Medicine and Hygiene 2003, 97:338-342.
238. Taylor S.M., Antonia A., Feng G., Mwapasa V., Chaluluka E., Molyneux M., Ter Kuile F.O., Rogerson S.J., Meshnick S.R. Adaptive evolution and fixation of drug-resistant Plasmodium falciparum genotypes in pregnancy-associated malaria: 9-year results from the QuEERPAM study. Infection, Genetics and Evolution: Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases 2012, 12:282-290.
239. Tekete M., Djimdé A.A., Beavogui A.H., Maiga H., Sagara I., Fofana B., Ouologuem D., Dama S., Kone A., Dembele D., Wele M., Dicko A., Doumbo O.K. Efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria: revisiting molecular markers in an area of emerging AQ and SP resistance in Mali. Malaria Journal 2009, 8:34.
240. Toyoda T., Brobey R.K., Sano G., Horii T., Tomioka N., Itai A. Lead discovery of inhibitors of the dihydrofolate reductase domain of Plasmodium falciparum dihydrofolate reductase-thymidylate synthase. Biochemical and Biophysical Research Communications 1997, 235:515-519.
241. Triglia T., Cowman A.F. Primary structure and expression of the dihydropteroate synthetase gene of Plasmodium falciparum. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:7149-7153.
242. Triglia T., Wang P., Sims P.F., Hyde J.E., Cowman A.F. Allelic exchange at the endogenous genomic locus in Plasmodium falciparum proves the role of dihydropteroate synthase in sulfadoxine-resistant malaria. The EMBO Journal 1998, 17:3807-3815.
243. Urdaneta L., Plowe C., Goldman I., Lal A.A. Point mutations in dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum isolates from Venezuela. The American Journal of Tropical Medicine and Hygiene 1999, 61:457-462.
244. Van Den Broek I.V., van der Wardt S., Talukder L., Chakma S., Brockman A., Nair S., Anderson T.C. Drug resistance in Plasmodium falciparum from the Chittagong Hill Tracts, Bangladesh. Tropical Medicine & International Health: TM & IH 2004, 9:680-687.
245. Vasconcelos K.F., Plowe C.V., Fontes C.J., Kyle D., Wirth D.F., Pereira da Silva L.H., Zalis M.G. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase of isolates from the Amazon region of Brazil. Memorias do Instituto Oswaldo Cruz 2000, 95:721-728.
246. Verdrager J. Epidemiology of the emergence and spread of drug-resistant falciparum malaria in South-East Asia and Australasia. The Journal of Tropical Medicine and Hygiene 1986, 89:277-289.
247. Vinayak S., Alam M.T., Mixson-Hayden T., Mccollum A.M., Sem R., Shah N.K., Lim P., Muth S., Rogers W.O., Fandeur T., Barnwell J.W., Escalante A.A., Wongsrichanalai C., Ariey F., Meshnick S.R., Udhayakumar V. Origin and evolution of sulfadoxine resistant Plasmodium falciparum. PLoS Pathogens 2010, 6:e1000830.
248. Wang P., Brobey R.K., Horii T., Sims P.F., Hyde J.E. Utilization of exogenous folate in the human malaria parasite Plasmodium falciparum and its critical role in antifolate drug synergy. Molecular Microbiology 1999, 32:1254-1262.
249. Wang P., Lee C.S., Bayoumi R., Djimdé A., Doumbo O., Swedberg G., Dao L.D., Mshinda H., Tanner M., Watkins W.M., Sims P.F., Hyde J.E. Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins. Molecular and Biochemical Parasitology 1997, 89:161-177.
250. Wang P., Read M., Sims P.F., Hyde J.E. Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization. Molecular Microbiology 1997, 23:979-986.
251. Warhurst D.C. Antimalarial drug discovery: development of inhibitors of dihydrofolate reductase active in drug resistance. Drug Discovery Today 1998, 3:538-546.
252. Warhurst D.C. Resistance to antifolates in Plasmodium falciparum, the causative agent of tropical malaria. Science Progress 2002, 85:89-111.
253. Wellems T.E., Plowe C.V. Chloroquine-resistant malaria. The Journal of Infectious Diseases 2001, 184:770-776.
254. Wernsdorfer W.H. Epidemiology of drug resistance in malaria. Acta Tropica 1994, 56:143-156.
255. Wernsdorfer W.H., Payne D. The dynamics of drug resistance in Plasmodium falciparum. Pharmacology & Therapeutics 1991, 50:95-121.
256. Wernsdorfer W.H., Noedl H. Molecular markers for drug resistance in malaria: use in treatment, diagnosis and epidemiology. Current Opinion in Infectious Diseases 2003, 16:553-558.
257. White N.J. Antimalarial drug resistance: the pace quickens. The Journal of Antimicrobial Chemotherapy 1992, 30:571-785.
258. White N.J. Delaying antimalarial drug resistance with combination chemotherapy. Parassitologia 1999, 41:301-308.
259. White N.J., Nosten F., Looareesuwan S., Watkins W.M., Marsh K., Snow R.W., Kokwaro G., Ouma J., Hien T.T., Molyneux M.E., Taylor T.E., Newbold C.I., Ruebush T.K., Danis M., Greenwood B.M., Anderson R.M., Olliaro P. Averting a malaria disaster. Lancet 1999, 353:1965-1967.
260. White N.J. Antimalarial drug resistance. The Journal of Clinical Investigation 2004, 113:1084-1092.
261. WHO, 1973. Chemotherapy of malaria and resistance to antimalarials. Report of a WHO Scientific Group. WHO Technical Report Series, No. 529.
262. WHO, 1996. Assessment of therapeutic efficacy of antimalarial drugs for uncomplicated malaria in areas with intense transmission, WHO/MAL/96.1077. World Health Organization, Geneva.
263. WHO, 2001. The Use of Antimalarial Drugs: Report of an Informal Consultation, WHO/CDS/RBM/2001.33. World Health Organization, Geneva.
264. WHO, 2003. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria, WHO/HTM/RBM/2003.50. World Health Organization, Geneva.
265. WHO, 2004. A strategic framework for malaria control and prevention during pregnancy in the African region. WHO Regional Office for Africa, Brazzaville.
266. WHO, 2005. Susceptibility of Plasmodium falciparum to antimalarial drugs: report on global monitoring: 1996-2004, WHO/HTM/MAL/2005.1103. World Health Organization, Geneva.
267. WHO, 2009. Methods for surveillance of antimalarial drug efficacy. World Health Organization, Geneva.
268. WHO, 2010. Guidelines for the treatment of malaria. World Health Organization, Geneva.
269. WHO, 2010. WHO policy recommendation on intermittent preventive treatment during infancy with sulphadoxine-pyrimethamine (SP-IPTi) for Plasmodium falciparum malaria control in Africa. World Health Organization, Geneva.
270. WHO, 2010. World malaria report 2010. World Health Organization, Geneva.
271. WHO Expert Committee on Malaria, 2000. WHO Expert Committee on Malaria: twentieth report. World Health Organization, Geneva.
272. Wichmann O., Jelinek T., Peyerl-Hoffmann G., Muhlberger N., Grobusch M.P., Gascon J., Matteelli A., Hatz C., Laferl H., Schulze M., Burchard G., da Cunha S., Beran J., Mcwhinney P., Kollaritsch H., Kern P., Cuadros J., Alifrangis M., Gjorup I. Molecular surveillance of the antifolate-resistant mutation I164L in imported African isolates of Plasmodium falciparum in Europe: sentinel data from TropNetEurop. Malaria Journal 2003, 2:17.
273. Winstanley P.A. Chemotherapy for falciparum malaria: the armoury, the problems and the prospects. Parasitology Today 2000, 16:146-153.
274. Wong R.P., Karunajeewa H., Mueller I., Siba P., Zimmerman P.A., Davis T.M. Molecular assessment of Plasmodium falciparum resistance to antimalarial drugs in Papua New Guinea using an extended ligase detection reaction fluorescent microsphere assay. Antimicrobial Agents and Chemotherapy 2011, 55:798-805.
275. Wongsrichanalai C., Pickard A.L., Wernsdorfer W.H., Meshnick S.R. Epidemiology of drug-resistant malaria. The Lancet Infectious Diseases 2002, 2:209-218.
276. Wooden J.M., Hartwell L.H., Vasquez B., Sibley C.H. Analysis in yeast of antimalaria drugs that target the dihydrofolate reductase of Plasmodium falciparum. Molecular and Biochemical Parasitology 1997, 85:25-40.
277. Wootton J.C., Feng X., Ferdig M.T., Cooper R.A., Mu J., Baruch D.I., Magill A.J., Su X.-Z. Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature 2002, 418:320-323.
278. Wu Y., Kirkman L.A., Wellems T.E. Transformation of Plasmodium falciparum malaria parasites by homologous integration of plasmids that confer resistance to pyrimethamine. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:1130-1134.
279. Wurtz N., Fall B., Pascual A., Diawara S., Sow K., Baret E., Diatta B., Fall K.B., Mbaye P.S., Fall F., Dieme Y., Rogier C., Bercion R., Briolant S., Wade B., Pradines B. Prevalence of molecular markers of Plasmodium falciparum drug resistance in Dakar, Senegal. Malaria Journal 2012, 11:197.
280. Young M.D., Contacos P.G., Stitcher J.E., Millar J.W. Drug resistance in Plasmodium falciparum from Thailand. The American Journal of Tropical Medicine and Hygiene 1963, 12:305-314.
281. Yusuf R.U., Omar S.A., Ngure R.M. The effect of point mutations in dihydrofolate reductase genes and multidrug resistance gene 1-86 on treatment of falciparum malaria in Sudan. Journal of Infection in Developing Countries 2010, 4:61-69.
282. Yuthavong Y. Basis for antifolate action and resistance in malaria. Microbes and Infection 2002, 4:175-182.
283. Zakeri S., Afsharpad M., Raeisi A., Djadid N.D. Prevalence of mutations associated with antimalarial drugs in Plasmodium falciparum isolates prior to the introduction of sulphadoxine-pyrimethamine as first-line treatment in Iran. Malaria Journal 2007, 6:148.
284. Zakeri S., Gil J.P., Bereckzy S., Djadid N.D., Bjorkman A. High prevalence of double Plasmodium falciparum dhfr mutations at codons 108 and 59 in the Sistan-Baluchistan province, Iran. The Journal of Infectious Diseases 2003, 187:1828-1829.
285. Zeile I., Gahutu J.B., Shyirambere C., Steininger C., Musemakweri A., Sebahungu F., Karema C., Harms G., Eggelte T.A., Mockenhaupt F.P. Molecular markers of Plasmodium falciparum drug resistance in southern highland Rwanda. Acta Tropica 2012, 121:50-54.
286. Zhang G.Q., Guan Y.Y., Zheng B., Wu S., Tang L.H. Molecular assessment of Plasmodium falciparum resistance to antimalarial drugs in China. Tropical Medicine & International Health: TM & IH 2009, 14:1266-1271.
287. Zhong D., Afrane Y., Githeko A., Cui L., Menge D.M., Yan G. Molecular epidemiology of drug-resistant malaria in western Kenya highlands. BMC Infectious Diseases 2008, 8:105.
288. Zhou Z., Griffing S.M., de Oliveira A.M., Mccollum A.M., Quezada W.M., Arrospide N., Escalante A.A., Udhayakumar V. Decline in sulfadoxine-pyrimethamine-resistant alleles after change in drug policy in the Amazon region of Peru. Antimicrobial Agents and Chemotherapy 2008, 52:739-741.
289. Zolg J.W., Plitt J.R., Chen G.X., Palmer S. Point mutations in the dihydrofolate reductase-thymidylate synthase gene as the molecular basis for pyrimethamine resistance in Plasmodium falciparum. Molecular and Biochemical Parasitology 1989, 36:253-262.